Future Tech Ventures Invests in SPCTR’s Instant Tumour Analysis Tech
Amsterdam, Wednesday 4 February 2026
Future Tech Ventures has funded SPCTR to accelerate an AI device that creates real-time tissue fingerprints, enabling surgeons to assess tumour margins instantly and significantly reducing the need for repeat surgeries.
Strategic Capital for Precision Medicine
On 3 February 2026, Future Tech Ventures (FTV) announced its investment in SPCTR, a Utrecht-based medical technology startup founded in March 2025 [1][2]. This marks the inaugural investment for FTV, a relatively young fund established in 2024 with a capital pool of €20 million [1]. Although the exact financial terms remain undisclosed, the backing serves as a crucial endorsement for SPCTR, which had previously relied on a loan from Rabobank [1]. The deal underscores a strategic push within the Netherlands to bridge the gap between academic innovation and clinical application, with FTV itself being a collaborative initiative founded by the University Medical Center Groningen (UMCG), RUG Ventures, the Northern Development Company (NOM), and the Groningen Investment Fund (IFG) [1].
Resolving the Margin Assessment Bottleneck
The core of SPCTR’s innovation addresses a persistent inefficiency in oncological surgery: the delay in pathology results. Rowan Timmermans, CTO and co-founder of SPCTR, highlights that surgeons often have to wait days to confirm if a tumour has been completely excised [2]. To counter this, SPCTR has developed a device that utilises light and imaging combined with an AI model to generate an ‘optical fingerprint’ of the tissue [2]. This technology allows for non-invasive, intra-operative margin analysis without requiring additional personnel or contrast agents, enabling surgeons to determine immediately if sufficient healthy tissue surrounds the tumour [2][3]. Initially, the company is focusing its efforts on breast cancer surgeries [2].
Accelerating Clinical Validation
The injection of capital coincides with a significant operational milestone: the commencement of the SPCTR-I study, which enrolled its first patient on 27 January 2026 [4]. The study represents the transition from preclinical development to clinical practice and is currently being conducted at the Breast Center Groningen, with UMC Utrecht (UMCU) designated as a second location for patient inclusion [1][4]. Wido Heeman, CEO and founder of SPCTR, stated that the investment will be allocated to three core activities: the clinical validation of prototypes, device certification, and preparing the technology for market introduction [4].